Adjunctive memantine for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials

Psychological Medicine

Volumn 48, Issue 1, 2018, Pages 72-81

  Zheng, W ^a   Li, X H ^b,c   Yang, X H ^a   Cai, D B ^d   Ungvari, G S ^e,f   Ng, C H ^g   Wang, S B ^h   Wang, Y Y ^h   Ning, Y P ^a   Xiang, Y T ^h  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b The National Clinical Research Center for Mental Disorders   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^e UNIVERSITY OF NOTRE DAME   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h University of Macau   (Macao)

Author keywords

Memantine; meta analysis; negative symptoms; NMDA receptor antagonists; schizophrenia

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; HUMAN; META ANALYSIS; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MEMANTINE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 85021053158     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291717001271     Document Type: Article

References (48)

1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams Jr. JW, Zaza S (2004). Grading quality of evidence and strength of recommendations. British Medical Journal 328, 1490.
2. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011). GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 64, 401-406.
3. Carroll BT, Goforth HW, Thomas C, Ahuja N, McDaniel WW, Kraus MF, Spiegel DR, Franco KN, Pozuelo L, Munoz C (2007). Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. Journal of Neuropsychiatry and Clinical Neurosciences 19, 406-412.
4. de Lucena D, Fernandes BS, Berk M, Dodd S, MedeirosDW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS (2009). Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. Journal of Clinical Psychiatry 70, 1416-1423.
5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177-188.
6. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634.
7. Field JR, Walker AG, Conn PJ (2011). Targeting glutamate synapses in schizophrenia. Trends in Molecular Medicine 17, 689-698.
8. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198.
9. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F (2007). Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 420, 45-48.
10. Gama CS, Antunes P, Moser C, Belmonte-de-Abreu PS (2005). Memantine as an adjunctive therapy for schizophrenia negative symptoms. Revista Brasileira de Psiquiatria 27, 257-258.
11. Gu J, Wu Y, Tang L (2012). A controlled study of clozapine plus memantine in schizophrenia negative symptoms [In Chinese]. Journal of Clinical Psychiatry 22, 261-263.
12. Guy W (1976). Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology (Revised) (ed. W. Guy), pp. 217-221. National Institute of Mental Health: Rockville.
13. Higgins J, Higgins J (2008). Cochrane Handbook for Systematic Reviews of Interventions. J. Wiley &Sons: Chichester, UK.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 17, 1-12.
15. John JP, Lukose A, Manjunath S (2014). Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. Pharmacopsychiatry 47, 202-209.
16. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
17. Kishi T, Iwata N (2013). NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. Journal of Psychiatric Research 47, 1143-1149.
18. Koch HJ, Uyanik G, Fischer-Barnicol D (2005). Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia. Current Drug Targets CNS and Neurological Disorders 4, 499-506.
19. Krivoy A, Weizman A, Laor L, Hellinger N, Zemishlany Z, Fischel T (2008). Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. European Neuropsychopharmacology 18, 117-121.
20. Lee JG, Lee SW, Lee BJ, Park SW, Kim GM, Kim YH (2012). Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investigation 9, 166-173.
21. Lelorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F (1997). Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New England Journal of Medicine 337, 536-542.
22. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, KisslingW, Stapf MP, Lassig B, Salanti G, Davis JM (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951-962.
23. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.
24. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152-163.
25. Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A (2009). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34, 1322-1329.
26. Lipton SA (2004). Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. Journal of Alzheimers Disease 6, S61-S74.
27. Marder SR, Fenton W (2004). Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Research 72, 5-9.
28. Matsuda Y, Kishi T, Iwata N (2013). Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. Journal of Psychiatric Research 47, 2018-2020.
29. Mazinani R, Nejati S, Khodaei M (2016). Effects of memantine added to risperidone on the symptoms of schizophrenia: a randomized double-blind, placebocontrolled clinical trial. Psychiatry Research 247, 291-295.
30. Moghaddam B, Javitt D (2012). From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37, 4-15.
31. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 151, 264-269, W64.
32. Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy M (2015). The effect of add-on memantine on global function and quality of life in schizophrenia: a randomized, double-blind, controlled, clinical trial. Advanced Biomedical Research 4, 2277-9175.
33. Overall JE, Gorham DR (1962). The brief psychiatric rating-scale. Psychological Reports 10, 799-812.
34. Pieta Dias C, Martins de Lima MN, Presti-Torres J, Dornelles A, Garcia VA, Siciliani Scalco F, Rewsaat Guimaraes M, Constantino L, Budni P, Dal-Pizzol F, Schroder N (2007). Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 146, 1719-1725.
35. Puangthong U, Hsiung GYR (2009). Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. Neuropsychiatric Disease and Treatment 5, 553-561.
36. Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S (2013). Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 33, 336-342.
37. Singh SP, Singh V (2011). Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 25, 859-885.
38. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP (2011). Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal 343, d4002.
39. Tsai G, Coyle JT (2002). Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology 42, 165-179.
40. Tsai GE, Lin PY (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Current Pharmaceutical Design 16, 522-537.
41. Veerman SR, Schulte PF, Smith JD, de Haan L (2016). Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychological Medicine 46, 1909-1921.
42. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J (2005). The economic burden of schizophrenia in the United States in 2002. Journal of Clinical Psychiatry 66, 1122-1129.
43. Xiang YQ, Zheng W, Wang SB, Yang XH, Cai DB, Ng CH, Ungvari GS, Kelly DL, Xu WY, Xiang YT (2017). Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. European Neuropsychopharmacology 27, 8-18.
44. Zdanys K, Tampi RR (2008). A systematic review of off-label uses of memantine for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 1362-1374.
45. Zheng W, Li Q, Lin JX, Xiang YQ, Guo T, Chen Q, Cai DB, Xiang YT (2016a). Tai Chi for schizophrenia: a systematic review. Shanghai Archives of Psychiatry 28, 185-194.
46. Zheng W, Wang SB, Ungvari GS, Ng CH, Yang XH, Gu YH, Li M, Xiang YQ, Xiang YT (2017). Amantadine for antipsychotic-related weight Gain: meta-analysis of randomized placebo-controlled trials. Journal of Clinical Psychopharmacology 37, 341-346.
47. ZhengW, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, Correll CU (2016b). Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatrica Scandinavica 134, 385-398.
48. Zheng W, Zheng YJ, Li XB, Tang YL, Wang CY, Xiang YQ, de Leon J (2016c). Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-analysis of randomized controlled trials. Journal of Clinical Psychopharmacology 36, 628-636.